PARD — Poniard Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.34m
Annual income statement for Poniard Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2006 December 31st | C2007 December 31st | C2008 December 31st | 2009 December 31st | 2010 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 21.2 | 35.4 | 49.2 | 43 | 28 |
| Operating Profit | -21.2 | -35.4 | -49.2 | -43 | -28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -23.3 | -32.8 | -48.6 | -45.7 | -30.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.3 | -32.8 | -48.6 | -45.7 | -30.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.3 | -32.8 | -48.6 | -45.7 | -30.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -23.8 | -33.3 | -49.1 | -46.2 | -30.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -54 | -43.4 | -55.4 | -48.4 | -23.9 |
| Dividends per Share |